Nivolumab Indication in Small Cell Lung Cancer Withdrawn in U.S. Market - The ASCO Post
Opdivo was granted accelerated approval in 2018 for small cell lung cancer based on surrogate endpoints, but has now been withdrawn from the US market, having failed to achieve its primary endpoint of Overall Survival in confirmatory studies.
This emphasises the urgent need that BMS and Merck have to find ways to make Opdivo and Keytruda work in more patients and in more forms of cancer.
Nivolumab Indication in Small Cell Lung Cancer Withdrawn in U.S....
Add to My Watchlist
What is My Watchlist?
